Predictors of Intracranial Atherosclerotic Disease in Posterior Circulation: a Cohort Study

Early identification of intracranial atherosclerotic disease (ICAD) may impact the management of patients undergoing mechanical thrombectomy (MT). The aim of the study is to develop and validate a scoring system for pre-thrombectomy diagnosis of ICAD in posterior circulation large vessel/distal medium vessel occlusion strokes (LVOs/DMVOs).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Stroke, Ischemic Arterial Occlusive Diseases Arteriosclerosis Brain Diseases Brain Infarction Brain Ischemia Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Infarction Intracranial Arterial Diseases Intracranial Arteriosclerosis Intracranial Atherosclerosis Ischemia Ischemic Stroke Necrosis Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Posterior Circulation Brain Infarction Stroke Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Sohag university hospitals, Sohag, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult ≥18 years
Patient with posterior circulation strokes who underwent mechanical thrombectomy.

Exclusion criteria

Patients with anterior circulation stroke.
Patients with intracranial hemorrhage
Patients without baseline radiological data.
Extracranial large vessel atherosclerosis related strokes.

Treatment and study plan

we are aiming to develop a Scoring system based on certain variables derived from both groups

Other

We are aiming to develop a Scoring system based on certain variables derived from both group

Primary outcomes

Post-procedural outcomes included any intracranial hemorrhage, symptomatic ICH (sICH)

Time frame: June 1st, 2025

sICH is defined as local or remote parenchymal hemorrhage type 2, subarachnoid hemorrhage, and/or intraventricular hemorrhage, combined with a neurological deterioration of 4 points or more on the NIHSS from baseline or leading to death that the physician judged was causative of the deterioration) per ECASS III criteria

Secondary outcomes

90 day modified Rankin scale (mRS)

Time frame: June 1st, 2025

a score of 0 to 4 on the modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 4 moderately severe disability, and 6 death) at 90 days, was changed to a good functional status (a modified Rankin scale score of 0 to 3, with a score of 3 indicating moderate disability)
90 day mortality

Time frame: June 1st, 2025

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Collaborators

Emory University

Registry information

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2026
First posted: Jun 11, 2024
Registry last updated: Jul 10, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting